<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1933">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04340349</url>
  </required_header>
  <id_info>
    <org_study_id>25/20</org_study_id>
    <nct_id>NCT04340349</nct_id>
  </id_info>
  <brief_title>Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals</brief_title>
  <acronym>ELEVATE</acronym>
  <official_title>Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Rehabilitacion</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Rehabilitacion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the security and efficacy of a daily low dose of&#xD;
      hydroxychloroquine and Bromhexine, in preventing the development of the disease from COVID-19&#xD;
      in Health Care Workers at a National Institute of Health In Mexico City.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will combine two drugs (hydroxychloroquine and Bromhexine) to see if&#xD;
      hydroxychloroquine is better in combination with Bromhexine in preventing the development of&#xD;
      the disease from COVID-19 in Health Care Workers at a National Institute of Health In Mexico&#xD;
      City. Hydroxychloroquine will be used in a low dose (200 mg every 24 hrs). Bromhexine will be&#xD;
      8mg every 8 hrs. The study groups will be the following: 1) HCQ 200mg/d + BHH placebo 2) HCQ&#xD;
      placebo plus BHH placebo&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>DOUBLE BLINDED</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of the expression of mRNA SARS-CoV-2 and presence or absence of antibodies anti-SARS-CoV-2</measure>
    <time_frame>Day 60</time_frame>
    <description>Primary endpoint will be the proportion of health personnel infected by SARS-CoV-2 at day 60 after starting treatment, in both groups. The infection will be diagnosed using qRT-PCR for relative expression of the mRNA of SARS-CoV-2 and the measure of IgM and IgG antibodies anti-SARS-CoV-2 after day 7 of treatment using rapid test Cellex qSARS-CoV-2 IgG/IgM</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of the expression of mRNA SARS-CoV-2 and presence or absence of antibodies anti-SARS-CoV-2</measure>
    <time_frame>Day 90</time_frame>
    <description>The secondary endpoint will be the proportion of health personnel infected 90 days after starting treatment in both groups. The infection will be diagnosed using qRT-PCR for relative expression of the mRNA of SARS-CoV-2 and the measure of IgM and IgG antibodies anti-SARS-CoV-2 after day 7 of the start of treatment using rapid test Cellex qSARS-CoV-2 IgG/IgM</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Positive SARS-CoV-2 result during the treatment</measure>
    <time_frame>Day 30 and day 90</time_frame>
    <description>The proportion of health personnel positive for SARS-CoV-2 and result in the need for oxygen use, admission to the intensive care unit (ICU), presence of pneumonia by computer tomography scan (CT), death, severe pneumonia defined by the American Thoracic Association, time from hospitalization to recovery in days.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 60</time_frame>
    <description>The proportion of health personnel presenting any of the following during the study period: death, nausea, vomiting, abdominal pain, diarrhea, rash, itchy skin, hair loss, lengthening of the QT interval in the electrocardiogram (&gt;500msec), corneal opacity, cardiac arrhythmias, heart failure or kidney failure (renal clearance &lt;20ml/min). The proportion of the compound of adverse events between the groups will be analyed using RR and ARI for 60 days with their respective 95% confidence intervals</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Hydroxychloroquine</condition>
  <condition>Antimalarials</condition>
  <condition>Enzyme Inhibitors</condition>
  <condition>Antirheumatic Agents</condition>
  <arm_group>
    <arm_group_label>Experimental: Hydroxychloroquine plus Bromhexine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg of Hydroxychloroquine daily for 2 months 8 mg of Bromhexine every 8 hrs for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine plus Bromhexine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>200 mg of Hydroxycholoroquine daily for 2 months 8 mg of Bromhexine every 8 hrs for 2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine Sulfate</intervention_name>
    <description>A daily low dose of Hydroxychloroquine Sulfate. Increase the endosomal pH and inhibits of ACE2 glycosylation receptor.</description>
    <arm_group_label>Experimental: Hydroxychloroquine plus Bromhexine</arm_group_label>
    <arm_group_label>Hydroxychloroquine plus Bromhexine</arm_group_label>
    <other_name>Evoquin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromhexine 8 MG</intervention_name>
    <description>TMPRSS2 blocker</description>
    <arm_group_label>Experimental: Hydroxychloroquine plus Bromhexine</arm_group_label>
    <arm_group_label>Hydroxychloroquine plus Bromhexine</arm_group_label>
    <other_name>Bisolvon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Health personnel working at INR LGII or INCMNSZ who wish to participate in the study&#xD;
             and sign the informed consent.&#xD;
&#xD;
          -  Over 18 and under 60 years of age, both genders.&#xD;
&#xD;
          -  Contacting with suspected or confirmed SARS-CoV-2 infection.&#xD;
&#xD;
          -  Normal electrocardiogram.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Positive quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) test&#xD;
             for SARS-CoV-2 at the time of inclusion.&#xD;
&#xD;
          -  Panel of IgG or IgM antibodies positive for SARS-CoV-2 at the time of inclusion.&#xD;
&#xD;
          -  Development of respiratory symptoms suspicious of SARS-CoV-2 infection during the&#xD;
             first 7 days after treatment is initiated, confirmed by qRT-PCR and IgG or IgM&#xD;
             antibodies postiver for SARS-CoV-2.&#xD;
&#xD;
          -  Health personnel with comorbidities such as diabetes, hypertension, autoimmune&#xD;
             diseases (i.e., porphyria, psoriasis, systemic lupus erythematosus), obesity (defined&#xD;
             as body mass index â‰¥30), cardiovascular diseases, respiratory diseases (such as&#xD;
             asthma, chronic bronchitis, idiopathic pulmonary fibrosis).&#xD;
&#xD;
          -  History of allergies to any hydroxychloroquine or bromhexine related compound or&#xD;
             medication.&#xD;
&#xD;
          -  Use of immunosuppressors for any reason.&#xD;
&#xD;
          -  History of bone marrow transplant.&#xD;
&#xD;
          -  Known glucose-6-phosphate dehydrogenase deficiency.&#xD;
&#xD;
          -  Chronic kidney disease or glomerular filtration &lt;20ml/min.&#xD;
&#xD;
          -  Use of other drugs with reported pharmacological interactions (i.e., digitalis,&#xD;
             flecainide, amiodarone, procainamide, or propafenone).&#xD;
&#xD;
          -  History of long QT syndrome.&#xD;
&#xD;
          -  Electrocardiogram with QTc&gt;500 msec.&#xD;
&#xD;
          -  Pregnant or breastfeeding personnel.&#xD;
&#xD;
          -  Epilepsy.&#xD;
&#xD;
          -  Known liver disease.&#xD;
&#xD;
          -  Personnel who have received the Covid-19 vaccine&#xD;
&#xD;
        Elimination criteria&#xD;
&#xD;
          -  Personnel who decide to leave the study for any reason not related to adverse events.&#xD;
&#xD;
          -  Personnel with incomplete information on the primary outcome (qRT-PCR for SARS-CoV-2).&#xD;
&#xD;
          -  Personnel who are relocated to work in another institution.&#xD;
&#xD;
          -  Personnel who do not wish to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio Granados-Montiel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Rehabilitation, Mexico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute of Rehabilitation, Luis Guillermo Ibarra Ibarra</name>
      <address>
        <city>Mexico City</city>
        <state>Cdmx</state>
        <zip>14389</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>https://covid19.who.int/region/amro/country/mx</url>
    <description>Dashboard Mexico 2021</description>
  </link>
  <reference>
    <citation>Pal M, Berhanu G, Desalegn C, Kandi V. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus. 2020 Mar 26;12(3):e7423. doi: 10.7759/cureus.7423. Review.</citation>
    <PMID>32337143</PMID>
  </reference>
  <reference>
    <citation>Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020 Apr 11;395(10231):1225-1228. doi: 10.1016/S0140-6736(20)30627-9. Epub 2020 Mar 13. Review.</citation>
    <PMID>32178769</PMID>
  </reference>
  <reference>
    <citation>Luzzi GA, Peto TE. Adverse effects of antimalarials. An update. Drug Saf. 1993 Apr;8(4):295-311. Review.</citation>
    <PMID>8481216</PMID>
  </reference>
  <reference>
    <citation>Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.</citation>
    <PMID>32074550</PMID>
  </reference>
  <reference>
    <citation>Dutta D, Sharma M, Sharma R. Short-term Hydroxychloroquine in COVID-19 Infection in People With or Without Metabolic Syndrome - Clearing Safety Issues and Good Clinical Practice. Eur Endocrinol. 2020 Oct;16(2):109-112. doi: 10.17925/EE.2020.16.2.109. Epub 2020 Oct 6. Review.</citation>
    <PMID>33117441</PMID>
  </reference>
  <reference>
    <citation>Paiardini M, MÃ¼ller-Trutwin M. HIV-associated chronic immune activation. Immunol Rev. 2013 Jul;254(1):78-101. doi: 10.1111/imr.12079. Review.</citation>
    <PMID>23772616</PMID>
  </reference>
  <reference>
    <citation>Chang R, Sun WZ. Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges. Drug Discov Today. 2020 Jul 3. pii: S1359-6446(20)30258-0. doi: 10.1016/j.drudis.2020.06.030. [Epub ahead of print]</citation>
    <PMID>32629169</PMID>
  </reference>
  <reference>
    <citation>Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ. 2020 Apr 27;192(17):E450-E453. doi: 10.1503/cmaj.200528. Epub 2020 Apr 8. Review. Erratum in: CMAJ. 2020 May 25;192(21):E590.</citation>
    <PMID>32269021</PMID>
  </reference>
  <reference>
    <citation>Zanasi A, Mazzolini M, Kantar A. A reappraisal of the mucoactive activity and clinical efficacy of bromhexine. Multidiscip Respir Med. 2017 Mar 20;12:7. doi: 10.1186/s40248-017-0088-1. eCollection 2017. Review.</citation>
    <PMID>28331610</PMID>
  </reference>
  <reference>
    <citation>Depfenhart M, de Villiers D, Lemperle G, Meyer M, Di Somma S. Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy? Intern Emerg Med. 2020 Aug;15(5):801-812. doi: 10.1007/s11739-020-02383-3. Epub 2020 May 26. Review.</citation>
    <PMID>32458206</PMID>
  </reference>
  <reference>
    <citation>Ravi N, Cortade DL, Ng E, Wang SX. Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape. Biosens Bioelectron. 2020 Oct 1;165:112454. doi: 10.1016/j.bios.2020.112454. Epub 2020 Jul 18. Review.</citation>
    <PMID>32729549</PMID>
  </reference>
  <results_reference>
    <citation>Lai C, Yu R, Wang M, Xian W, Zhao X, Tang Q, Chen R, Zhou X, Li X, Li Z, Li Z, Deng G, Wang F. Shorter incubation period is associated with severe disease progression in patients with COVID-19. Virulence. 2020 Dec;11(1):1443-1452. doi: 10.1080/21505594.2020.1836894.</citation>
    <PMID>33108255</PMID>
  </results_reference>
  <results_reference>
    <citation>Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.</citation>
    <PMID>32109013</PMID>
  </results_reference>
  <results_reference>
    <citation>Li C, Ji F, Wang L, Wang L, Hao J, Dai M, Liu Y, Pan X, Fu J, Li L, Yang G, Yang J, Yan X, Gu B. Asymptomatic and Human-to-Human Transmission of SARS-CoV-2 in a 2-Family Cluster, Xuzhou, China. Emerg Infect Dis. 2020 Jul;26(7):1626-1628. doi: 10.3201/eid2607.200718. Epub 2020 Jun 21.</citation>
    <PMID>32228809</PMID>
  </results_reference>
  <results_reference>
    <citation>Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, Li T, Chen Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020 Feb 24;12(1):8. doi: 10.1038/s41368-020-0074-x.</citation>
    <PMID>32094336</PMID>
  </results_reference>
  <results_reference>
    <citation>Levy A, Yagil Y, Bursztyn M, Barkalifa R, Scharf S, Yagil C. ACE2 expression and activity are enhanced during pregnancy. Am J Physiol Regul Integr Comp Physiol. 2008 Dec;295(6):R1953-61. doi: 10.1152/ajpregu.90592.2008. Epub 2008 Oct 22.</citation>
    <PMID>18945956</PMID>
  </results_reference>
  <results_reference>
    <citation>Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosci. 2020 Apr 1;11(7):995-998. doi: 10.1021/acschemneuro.0c00122. Epub 2020 Mar 13.</citation>
    <PMID>32167747</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhan M, Qin Y, Xue X, Zhu S. Death from Covid-19 of 23 Health Care Workers in China. N Engl J Med. 2020 Jun 4;382(23):2267-2268. doi: 10.1056/NEJMc2005696. Epub 2020 Apr 15.</citation>
    <PMID>32294342</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.</citation>
    <PMID>32091533</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu Q, Bi G, Chen G, Guo X, Tu S, Tong X, Xu M, Liu M, Wang B, Jiang H, Wang J, Li H, Wang K, Liu D, Song C. Time-Dependent Distribution of Hydroxychloroquine in Cynomolgus Macaques Using Population Pharmacokinetic Modeling Method. Front Pharmacol. 2021 Jan 14;11:602880. doi: 10.3389/fphar.2020.602880. eCollection 2020.</citation>
    <PMID>33519466</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang LF, Lin YS, Huang NC, Yu CY, Tsai WL, Chen JJ, Kubota T, Matsuoka M, Chen SR, Yang CS, Lu RW, Lin YL, Chang TH. Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. J Interferon Cytokine Res. 2015 Mar;35(3):143-56. doi: 10.1089/jir.2014.0038. Epub 2014 Oct 16.</citation>
    <PMID>25321315</PMID>
  </results_reference>
  <results_reference>
    <citation>Helal GK, Gad MA, Abd-Ellah MF, Eid MS. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. J Med Virol. 2016 Dec;88(12):2170-2178. doi: 10.1002/jmv.24575. Epub 2016 May 25.</citation>
    <PMID>27183377</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.</citation>
    <PMID>32020029</PMID>
  </results_reference>
  <results_reference>
    <citation>Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.</citation>
    <PMID>32150618</PMID>
  </results_reference>
  <results_reference>
    <citation>Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, Zhang P, Liu X, Gao G, Liu F, Jiang Y, Cheng X, Zhu C, Xia Y. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020 Dec;9(1):1123-1130. doi: 10.1080/22221751.2020.1770129.</citation>
    <PMID>32475230</PMID>
  </results_reference>
  <results_reference>
    <citation>Chude CI, Amaravadi RK. Targeting Autophagy in Cancer: Update on Clinical Trials and Novel Inhibitors. Int J Mol Sci. 2017 Jun 16;18(6). pii: E1279. doi: 10.3390/ijms18061279. Review.</citation>
    <PMID>28621712</PMID>
  </results_reference>
  <results_reference>
    <citation>Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, Labella A, Manson DK, Kubin C, Barr RG, Sobieszczyk ME, Schluger NW. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 Jun 18;382(25):2411-2418. doi: 10.1056/NEJMoa2012410. Epub 2020 May 7.</citation>
    <PMID>32379955</PMID>
  </results_reference>
  <results_reference>
    <citation>Zahr N, Urien S, Llopis B, Pourcher V, Paccoud O, Bleibtreu A, Mayaux J, Gandjbakhch E, Hekimian G, Combes A, Benveniste O, Saadoun D, Allenbach Y, Pinna B, Cacoub P, Funck-Brentano C, Salem JE. Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. Therapie. 2021 Jan 28. pii: S0040-5957(21)00066-4. doi: 10.1016/j.therap.2021.01.056. [Epub ahead of print]</citation>
    <PMID>33558079</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoffmann M, Kleine-Weber H, Schroeder S, KrÃ¼ger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, MÃ¼ller MA, Drosten C, PÃ¶hlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.</citation>
    <PMID>32142651</PMID>
  </results_reference>
  <results_reference>
    <citation>Mareev VY, Orlova YA, Pavlikova EP, Matskeplishvili ST, Akopyan ZA, Plisyk AG, Seredenina EM, Asratyan DA, Potapenko AV, Malakhov PS, Samokhodskaya LM, Mershina EA, Sinitsyn VE, Bulanova MM, Fuks AA, Mareev YV, Begrambekova YL, Kamalov AA. [Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial &quot;BromhexIne and Spironolactone for CoronÐ°virUs Infection requiring hospiTalization (BISCUIT)&quot;]. Kardiologiia. 2020 Sep 7;60(8):4-15. doi: 10.18087/cardio.2020.8.n1307. Russian.</citation>
    <PMID>33155953</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Rehabilitacion</investigator_affiliation>
    <investigator_full_name>Julio Granados Montiel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Hydroxychloroquine</keyword>
  <keyword>BROMHEXINE</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Bromhexine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Under Mexican Law, we are not able to provide IPD</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 1, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT04340349/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

